
  
    
      
        Background_NNP
        Clozapine_NNP is_VBZ a_DT widely_RB used_VBN atypical_JJ neuroleptic_JJ with_IN
        affinity_NN for_IN multiple_JJ receptors_NNS ,_, including_VBG dopamine_NN ,_,
        serotonin_NN ,_, alpha_NN adrenergic_JJ ,_, muscarinic_JJ and_CC histaminergic_JJ
        receptors_NNS [_NN 1_CD 2_CD ]_NN ._. Although_IN clozapine_NN is_VBZ effective_JJ in_IN the_DT
        treatment_NN of_IN schizophrenia_NN refractory_JJ to_TO traditional_JJ
        antipsychotic_JJ medication_NN ,_, it_PRP also_RB has_VBZ a_DT number_NN of_IN
        significant_JJ side_NN effects_NNS ranging_VBG from_IN the_DT potentially_RB fatal_JJ
        but_CC rare_JJ agranulocytosis_NNS to_TO weight_VB gain_NN ,_, constipation_NN ,_,
        seizures_NNS and_CC urinary_JJ incontinence_NN [_NN 3_CD ]_NN ._. Urinary_NNP problems_NNS
        have_VBP been_VBN reported_VBN in_IN the_DT clinical_JJ literature_NN with_IN
        incontinence_NN present_JJ in_IN up_IN to_TO 44_CD %_NN of_IN patients_NNS [_NN 4_CD ]_NN and_CC
        enuresis_NNS in_IN 27_CD %_NN of_IN patients_NNS [_NN 5_CD ]_NN ._. Since_IN clozapine_NN has_VBZ
        potent_JJ anti-muscarinic_JJ and_CC anti-alpha_JJ adrenergic_JJ effects_NNS [_NN
        2_CD ]_NN ,_, it_PRP has_VBZ been_VBN proposed_VBN that_IN peripheral_JJ effects_NNS on_IN the_DT
        lower_JJR urinary_JJ tract_NN might_MD be_VB responsible_JJ for_IN the_DT
        micturition_NN disturbances_NNS [_NN 6_CD ]_NN ._. Incontinence_NNP has_VBZ also_RB been_VBN
        reported_VBN following_VBG therapy_NN with_IN other_JJ atypical_JJ neuroleptics_NNS
        such_JJ as_IN risperidone_NN [_NN 7_CD 8_CD 9_CD ]_NN and_CC recently_RB ,_, olanzapine_NN [_NN 10_CD
        ]_NN ._.
        We_PRP have_VBP previously_RB shown_VBN that_IN intravenous_JJ administration_NN
        of_IN clozapine_NN to_TO anesthetized_JJ rats_NNS [_NN 11_CD 12_CD ]_NN altered_VBD several_JJ
        micturition_NN parameters_NNS including_VBG a_DT decreased_VBN amount_NN of_IN
        volume_NN voided_VBN per_IN micturition_NN and_CC a_DT concomitant_NN increase_NN in_IN
        the_DT residual_JJ volume_NN ._. In_IN addition_NN ,_, clozapine_NN also_RB inhibits_NNS
        the_DT external_JJ urethral_NN sphincter_NN ._. Other_JJ ,_, newer_JJR ,_, atypical_JJ
        neuroleptics_NNS (_( e_SYM ._. g_SYM ._. olanzapine_NN and_CC risperidone_NN ;_: [_NN 13_CD ]_NN )_)
        were_VBD also_RB found_VBN to_TO have_VB similar_JJ effects_NNS but_CC with_IN differing_VBG
        potency_NN compared_VBN to_TO clozapine_NN ._. Since_IN risperidone_NN has_VBZ little_JJ
        or_CC no_DT anti-muscarinic_JJ activity_NN ,_, a_DT primary_JJ anti-muscarinic_JJ
        peripheral_JJ effect_NN may_MD be_VB ruled_VBN out_IN as_IN the_DT cause_NN of_IN
        micturition_NN disturbances_NNS following_VBG risperidone_NN
        administration_NN ,_, and_CC suggest_VBP a_DT possible_JJ central_JJ role_NN for_IN
        atypical_JJ neuroleptics_NNS in_IN regulating_VBG micturition_NN ._.
        The_DT purpose_NN of_IN the_DT present_JJ study_NN was_VBD to_TO determine_VB the_DT
        effects_NNS of_IN clozapine_NN administered_VBN centrally_RB at_IN two_CD
        different_JJ sites_NNS ,_, spinal_JJ (_( L_NNP 6_CD -_: S_NNP 1_CD spinal_JJ segments_NNS )_) vs_NNS ._.
        supraspinal_NN (_( lateral_NN ventricle_NN )_) ,_, on_IN micturition_NN and_CC the_DT
        external_JJ urethral_NN sphincter_NN during_IN cystometry_NN in_IN the_DT
        anesthetized_JJ rat_NN ._. By_IN limiting_VBG the_DT application_NN site_NN to_TO a_DT
        specific_JJ area_NN of_IN the_DT central_JJ nervous_JJ system_NN and_CC comparing_VBG
        the_DT results_NNS with_IN our_PRP$ previous_JJ findings_NNS after_IN systemic_JJ
        administration_NN [_NN 12_CD ]_NN it_PRP might_MD be_VB possible_JJ to_TO determine_VB
        whether_IN the_DT effects_NNS of_IN clozapine_NN are_VBP mediated_JJ at_IN a_DT central_JJ
        or_CC peripheral_JJ level_NN ._. Moreover_RB ,_, a_DT comparison_NN of_IN the_DT two_CD
        central_JJ routes_NNS might_MD indicate_VB whether_IN the_DT central_JJ effect_NN
        involves_VBZ spinal_NN or_CC supraspinal_NN structures_NNS ._. We_PRP report_VBP in_IN
        this_DT study_NN that_IN most_JJS of_IN the_DT effects_NNS of_IN clozapine_NN on_IN
        micturition_NN are_VBP mediated_JJ by_IN its_PRP$ central_JJ effects_NNS ._.
        Furthermore_RB ,_, there_EX are_VBP differences_NNS in_IN spinal_NN versus_CC
        supraspinal_NN effects_NNS ._.
      
      
        Results_NNS
        
          Effects_NNPS of_IN central_JJ administration_NN of_IN clozapine_NN on_IN
          urodynamic_JJ parameters_NNS during_IN single_JJ cystometry_NN (_( Table_NNP
          1_CD and_CC 2_LS )_)
          Figures_NNS 1_CD and_CC 2_CD show_NN representative_NN examples_NNS of_IN the_DT
          effects_NNS of_IN clozapine_NN on_IN single_JJ cystometry_NN in_IN anesthetized_JJ
          rats_NNS after_IN intrathecal_NN (_( i_NNP ._. t_NN ._. ;_: L_NNP 6_CD -_: S_NNP 1_CD spinal_JJ segment_NN )_) and_CC
          intracerebroventricular_NN (_( i_NNP ._. c_SYM ._. v_NN ._. ;_: lateral_NN ventricle_NN )_)
          administration_NN ,_, respectively_RB ._.
          Bladder_NNP capacity_NN was_VBD increased_VBN by_IN clozapine_NN given_VBN i_NNP ._. t_NN ._.
          or_CC i_NNP ._. c_SYM ._. v_NN ._. only_RB at_IN the_DT highest_JJS dose_NN tested_VBN (_( Fig_NNP 1_CD G_NNP ;_: 2_CD G_NNP )_) ._.
          After_IN 50_CD nmoles_NNS of_IN clozapine_NN i_NNP ._. t_NN ._. the_DT bladder_NN capacity_NN
          was_VBD 0_CD ._. 47_CD ±_NN 0_CD ._. 09_CD ml_NN ,_, compared_VBN to_TO 0_CD ._. 29_CD ±_NN 0_CD ._. 027_CD ml_NN after_IN
          vehicle_NN administration_NN (_( Fig_NNP 3_CD A_DT )_) ._. Similarly_RB ,_, after_IN 50_CD
          nmoles_NNS of_IN clozapine_NN i_NNP ._. c_SYM ._. v_NN the_DT bladder_NN capacity_NN was_VBD 0_CD ._. 51_CD ±_NN
          0_CD ._. 11_CD ml_NN ,_, compared_VBN to_TO 0_CD ._. 25_CD +_NN 0_CD ._. 027_CD ml_NN after_IN vehicle_NN
          administration_NN (_( Fig_NNP 3_CD A_DT )_) ._.
          Micturition_NNP volume_NN was_VBD significantly_RB decreased_VBN after_IN
          5_CD ._. 0_CD and_CC 50_CD nmoles_NNS of_IN clozapine_NN i_NNP ._. t_NN ._. (_( Fig_NNP 3_CD B_NNP )_) to_TO 0_CD ._. 11_CD ±_NN
          0_CD ._. 031_CD and_CC 0_CD ._. 08_CD ±_NN 0_CD ._. 019_CD ml_NN ,_, respectively_RB compared_VBN to_TO 0_CD ._. 18_CD
          ±_NN 0_CD ._. 022_CD ml_NN after_IN vehicle_NN ._. In_IN the_DT case_NN of_IN
          intracerebroventricular_NN administration_NN ,_, 0_CD ._. 5_CD nmoles_NNS of_IN
          clozapine_NN decreased_VBD the_DT micturition_NN volume_NN to_TO 0_CD ._. 11_CD ±_NN 0_CD ._. 02_CD
          ml_NN compared_VBN to_TO 0_CD ._. 16_CD ±_NN 0_CD ._. 018_CD ml_NN after_IN vehicle_NN (_( Fig_NNP 3_CD B_NNP )_) ._.
          The_DT effect_NN of_IN 0_CD ._. 5_CD nmoles_NNS of_IN clozapine_NN i_NNP ._. c_SYM ._. v_NN ._. on_IN
          micturition_NN volume_NN was_VBD significantly_RB different_JJ from_IN the_DT
          effect_NN of_IN the_DT same_JJ dose_NN given_VBN i_NNP ._. t_NN ._. Further_RB reductions_NNS in_IN
          micturition_NN volume_NN were_VBD observed_VBN after_IN 50_CD nmoles_NNS of_IN
          clozapine_NN i_NNP ._. c_SYM ._. v_NN ._.
          Residual_NNP volume_NN was_VBD significantly_RB increased_VBN after_IN 5_CD ._. 0_CD
          and_CC 50_CD nmoles_NNS of_IN clozapine_NN i_NNP ._. t_NN ._. to_TO 69_CD ±_NN 6_CD ._. 2_CD %_NN and_CC 79_CD ±_NN
          4_CD ._. 3_CD %_NN ,_, compared_VBN to_TO 34_CD ±_NN 7_CD ._. 5_CD %_NN after_IN vehicle_NN administration_NN
          (_( Fig_NNP 3_CD C_NNP )_) ._. Clozapine_NNP i_NNP ._. c_SYM ._. v_NN ._. resulted_VBD in_IN a_DT significant_JJ
          increase_NN in_IN the_DT residual_JJ volume_NN at_IN all_DT doses_NNS ,_, including_VBG
          0_CD ._. 5_CD nmoles_NNS ._. After_IN 0_CD ._. 5_CD nmoles_NNS i_NNP ._. c_SYM ._. v_NN ._. the_DT residual_JJ volume_NN
          was_VBD 54_CD ±_NN 8_CD ._. 5_CD %_NN compared_VBN to_TO 33_CD ±_NN 7_CD ._. 4_CD %_NN after_IN vehicle_NN ._. This_DT
          residual_JJ volume_NN was_VBD not_RB significantly_RB different_JJ from_IN the_DT
          one_CD observed_VBD after_IN the_DT same_JJ dose_NN i_NNP ._. t_NN ._. Larger_NNP doses_NNS of_IN
          clozapine_NN i_NNP ._. c_SYM ._. v_NN ._. resulted_VBD in_IN further_JJ increases_NNS in_IN the_DT
          residual_JJ volume_NN to_TO 62_CD ±_NN 3_CD ._. 8_CD and_CC 80_CD ±_NN 5_CD ._. 2_CD %_NN after_IN 5_CD ._. 0_CD and_CC
          50_CD nmoles_NNS ,_, respectively_RB ._.
          Clozapine_NNP i_NNP ._. t_NN ._. or_CC i_NNP ._. c_SYM ._. v_NN caused_VBD an_DT increase_NN in_IN the_DT
          pressure_NN threshold_NN only_RB at_IN the_DT highest_JJS doses_NNS tested_VBN (_( Fig_NNP
          1_CD G_NNP ;_: 2_CD G_NNP ;_: 4_CD A_DT )_) ._. After_IN 50_CD nmoles_NNS i_NNP ._. t_NN ._. the_DT pressure_NN threshold_NN
          was_VBD 6_CD ._. 0_CD ±_NN 0_CD ._. 86_CD compared_VBN to_TO 3_CD ._. 4_CD ±_NN 0_CD ._. 46_CD mm_NN Hg_NNP after_IN
          vehicle_NN ,_, whereas_IN after_IN i_NNP ._. c_SYM ._. v_NN ._. administration_NN the_DT same_JJ
          dose_NN increased_VBD the_DT pressure_NN threshold_NN to_TO 7_CD ._. 2_CD ±_NN 1_CD ._. 46_CD mm_NN Hg_NNP
          compared_VBD to_TO 2_CD ._. 9_CD ±_NN 0_CD ._. 29_CD mm_NN Hg_NNP after_IN vehicle_NN ._.
          Clozapine_NNP i_NNP ._. t_NN ._. or_CC i_NNP ._. c_SYM ._. v_NN had_VBD no_DT effect_NN on_IN either_DT peak_NN
          pressure_NN or_CC contraction_NN time_NN in_IN the_DT range_NN of_IN doses_NNS tested_VBN
          (_( Fig_NNP 4_CD B_NNP ,_, 5_CD A_DT )_) in_IN this_DT study_NN ._.
          Expulsion_NNP time_NN was_VBD significantly_RB decreased_VBN by_IN
          clozapine_NN at_IN 5_CD ._. 0_CD and_CC 50_CD nmoles_NNS either_CC i_NNP ._. t_NN ._. or_CC i_NNP ._. c_SYM ._. v_NN (_( Fig_NNP
          5_CD B_NNP )_) ._. After_IN vehicle_NN i_NNP ._. t_NN ._. the_DT expulsion_NN time_NN was_VBD 2_CD ._. 4_CD ±_NN 0_CD ._. 3_CD
          sec_NN ,_, which_WDT decreased_VBD to_TO 0_CD ._. 7_CD ±_NN 0_CD ._. 46_CD and_CC 0_CD ._. 9_CD ±_NN 0_CD ._. 93_CD sec_NN
          after_IN 5_CD and_CC 50_CD nmoles_NNS i_NNP ._. t_NN ._. Similarly_RB ,_, after_IN vehicle_NN i_NNP ._. c_SYM ._. v_NN
          the_DT expulsion_NN time_NN was_VBD 3_CD ._. 0_CD ±_NN 0_CD ._. 28_CD sec_NN and_CC 5_CD ._. 0_CD and_CC 50_CD
          nmoles_NNS of_IN clozapine_NN i_NNP ._. c_SYM ._. v_NN decreased_VBD it_PRP to_TO 1_CD ._. 8_CD ±_NN 0_CD ._. 35_CD and_CC
          1_CD ._. 3_CD ±_NN 0_CD ._. 39_CD sec_NN ,_, respectively_RB ._. The_DT effect_NN of_IN 5_CD ._. 0_CD nmoles_NNS of_IN
          clozapine_NN i_NNP ._. t_NN ._. on_IN the_DT expulsion_NN time_NN was_VBD significantly_RB
          different_JJ from_IN the_DT effect_NN observed_VBD after_IN i_NNP ._. c_SYM ._. v_NN
          administration_NN of_IN this_DT dose_NN (_( Fig_NNP 5_CD B_NNP )_) ._.
          Clozapine_NNP also_RB decreased_VBD the_DT amplitude_NN of_IN (_( and_CC in_IN some_DT
          animals_NNS even_RB abolished_VBN )_) the_DT high_JJ frequency_NN oscillations_NNS
          (_( HFO_NNP )_) after_IN i_NNP ._. t_NN ._. administration_NN (_( Fig_NNP 1_CD ;_: 5_CD C_NNP )_) ._. After_IN 5_CD ._. 0_CD
          nmoles_NNS of_IN clozapine_NN the_DT HFO_NNP were_VBD 0_CD ._. 4_CD ±_NN 0_CD ._. 23_CD compared_VBN to_TO
          1_CD ._. 5_CD ±_NN 0_CD ._. 1_CD mm_NN Hg_NNP after_IN administration_NN of_IN vehicle_NN ._. In_IN 4_CD of_IN
          the_DT 6_CD animals_NNS in_IN this_DT group_NN ,_, 5_CD nmoles_NNS of_IN clozapine_NN i_NNP ._. t_NN ._.
          abolished_VBD the_DT HFO_NNP ._. The_DT reduction_NN in_IN amplitude_NN observed_VBD at_IN
          this_DT dose_NN after_IN i_NNP ._. t_NN ._. administration_NN of_IN significantly_RB
          different_JJ from_IN the_DT effects_NNS observed_VBD after_IN the_DT same_JJ dose_NN
          i_NNP ._. c_SYM ._. v_NN ._. (_( Fig_NNP 5_CD C_NNP )_) ._. A_DT greater_JJR dose_NN of_IN clozapine_NN did_VBD not_RB
          cause_VB a_DT larger_JJR effect_NN although_IN the_DT amplitude_NN of_IN the_DT HFO_NNP
          after_IN 50_CD nmoles_NNS of_IN clozapine_NN i_NNP ._. t_NN ._. was_VBD still_RB significantly_RB
          reduced_VBN (_( 0_CD ._. 5_LS ±_NN 0_CD ._. 19_CD mm_NN Hg_NNP )_) when_WRB compared_VBN to_TO vehicle_NN
          administration_NN ._. Clozapine_NNP i_NNP ._. c_SYM ._. v_NN decreased_VBD the_DT amplitude_NN
          of_IN the_DT HFO_NNP only_RB at_IN 50_CD nmoles_NNS (_( 0_CD ._. 6_CD ±_NN 0_CD ._. 2_CD mm_NN Hg_NNP compared_VBD to_TO
          1_CD ._. 6_CD ±_NN 0_CD ._. 11_CD mm_NN Hg_NNP after_IN vehicle_NN administration_NN ;_: Fig_NNP 2_LS )_) ,_,
          and_CC the_DT HFO_NNP were_VBD abolished_VBN in_IN only_RB 1_CD /_NN 6_CD of_IN the_DT animals_NNS in_IN
          this_DT group_NN ._.
        
        
          Effects_NNPS of_IN central_JJ administration_NN of_IN clozapine_NN on_IN
          the_DT activity_NN of_IN the_DT external_JJ urethral_NN sphincter_NN during_IN
          single_JJ cystometry_NN (_( Table_NNP 1_CD and_CC 2_LS )_)
          Clozapine_NNP i_NNP ._. t_NN ._. did_VBD not_RB have_VB an_DT effect_NN on_IN the_DT activity_NN
          of_IN the_DT EUS_NNP during_IN Phase_NN 1_CD (_( the_DT rising_VBG phase_NN during_IN a_DT
          contraction_NN )_) ,_, and_CC only_RB the_DT highest_JJS dose_NN of_IN clozapine_NN
          i_NNP ._. c_SYM ._. v_NN (_( 50_CD nmoles_NNS )_) was_VBD found_VBN to_TO decrease_VB the_DT activity_NN of_IN
          the_DT EUS_NNP (_( Fig_NNP 6_CD A_DT )_) to_TO 62_CD ±_NN 14_CD ._. 9_CD %_NN of_IN that_DT seen_VBN during_IN
          administration_NN of_IN vehicle_NN ._.
          Phase_NN 2_CD of_IN the_DT EUS_NNP EMG_NNP (_( occurring_VBG during_IN the_DT time_NN of_IN
          HFO_NNP )_) was_VBD decreased_VBN by_IN clozapine_NN either_DT i_NNP ._. t_NN or_CC i_NNP ._. c_SYM ._. v_NN ._. 5_LS
          and_CC 50_CD nmoles_NNS of_IN clozapine_NN i_NNP ._. t_NN ._. decreased_VBD the_DT EMG_NNP to_TO 37_CD ±_NN
          24_CD and_CC 40_CD ±_NN 14_CD %_NN of_IN that_DT observed_VBD during_IN administration_NN of_IN
          vehicle_NN ,_, respectively_RB (_( Fig_NNP 6_CD B_NNP )_) ._. In_IN fact_NN ,_, in_IN 4_CD /_NN 6_CD animals_NNS ,_,
          5_CD ._. 0_CD nmoles_NNS of_IN clozapine_NN i_NNP ._. t_NN ._. abolished_VBD the_DT bursting_VBG
          pattern_NN of_IN the_DT EMG_NNP observed_VBD during_IN phase_NN 2_CD (_( Fig_NNP 1_CD F_NN )_) ._.
          Clozapine_NNP administered_VBN i_NNP ._. c_SYM ._. v_NN at_IN a_DT dose_NN of_IN 0_CD ._. 5_CD nmoles_NNS
          decreased_VBD the_DT EUS_NNP EMG_NNP to_TO 68_CD ±_NN 13_CD ._. 9_CD %_NN of_IN the_DT activity_NN
          observed_VBD after_IN vehicle_NN administration_NN (_( Fig_NNP 6_CD B_NNP )_) ._. Larger_NNP
          doses_NNS (_( 5_CD and_CC 50_CD nmoles_NNS )_) of_IN clozapine_NN i_NNP ._. c_SYM ._. v_NN further_RBR
          reduced_VBD the_DT EUS_NNP activity_NN during_IN this_DT phase_NN to_TO 54_CD ±_NN 8_CD ._. 4_CD %_NN
          and_CC 26_CD ±_NN 9_CD ._. 9_CD %_NN ._. Clozapine_NNP i_NNP ._. c_SYM ._. v_NN ,_, however_RB ,_, was_VBD not_RB observed_VBN
          to_TO abolish_VB the_DT bursting_VBG pattern_NN during_IN this_DT phase_NN (_( Fig_NNP
          2_LS )_) ,_, except_IN in_IN 1_CD /_NN 6_CD animals_NNS ._.
          Phase_NN 3_CD of_IN the_DT EUS_NNP EMG_NNP (_( recorded_VBN during_IN the_DT falling_VBG
          phase_NN of_IN a_DT bladder_NN contraction_NN )_) was_VBD not_RB affected_VBN by_IN
          clozapine_NN administered_VBN intrathecally_RB (_( Fig_NNP 6_CD C_NNP )_) ._. However_RB ,_,
          the_DT largest_JJS dose_NN of_IN clozapine_NN given_VBN i_NNP ._. c_SYM ._. v_NN (_( 50_CD nmoles_NNS )_)
          decreased_VBD the_DT activity_NN to_TO 50_CD ±_NN 14_CD ._. 9_CD %_NN of_IN the_DT activity_NN
          observed_VBD during_IN vehicle_NN administration_NN ._.
          Finally_RB ,_, the_DT amplitude_NN of_IN the_DT bursts_NNS observed_VBD during_IN
          phase_NN 2_CD in_IN the_DT EUS_NNP EMG_NNP were_VBD decreased_VBN to_TO 32_CD ±_NN 20_CD ._. 5_LS %_NN by_IN
          5_CD ._. 0_CD nmoles_NNS of_IN clozapine_NN i_NNP ._. t_NN ._. (_( Fig_NNP 6_CD D_NNP )_) ._. A_DT similar_JJ dose_NN of_IN
          clozapine_NN i_NNP ._. c_SYM ._. v_NN had_VBD no_DT effect_NN ._. However_RB ,_, 50_CD nmoles_NNS of_IN
          clozapine_NN i_NNP ._. c_SYM ._. v_NN ._. decreased_VBD the_DT amplitude_NN of_IN the_DT bursts_NNS to_TO
          65_CD ±_NN 17_CD ._. 2_LS %_NN of_IN that_DT observed_VBD during_IN vehicle_NN
          administration_NN ._.
        
      
      
        Discussion_NNP
        In_IN the_DT present_JJ experiments_NNS ,_, central_JJ application_NN of_IN
        clozapine_NN (_( intrathecally_RB over_IN the_DT L_NNP 6_CD /_NN S_NNP 1_CD spinal_JJ segments_NNS or_CC
        intracerebroventricularly_RB into_IN the_DT lateral_NN ventricle_NN )_)
        resulted_VBD in_IN a_DT number_NN of_IN changes_NNS in_IN the_DT urodynamic_JJ
        parameters_NNS of_IN anesthetized_JJ rats_NNS ._. The_DT major_JJ effect_NN of_IN
        clozapine_NN was_VBD to_TO decrease_VB the_DT voiding_VBG efficiency_NN of_IN the_DT
        bladder_NN by_IN inhibiting_VBG expulsion_NN parameters_NNS ,_, such_JJ as_IN
        micturition_NN volume_NN ,_, residual_JJ volume_NN and_CC expulsion_NN time_NN ._. In_IN
        addition_NN ,_, the_DT activity_NN of_IN the_DT EUS_NNP also_RB decreased_VBD upon_IN
        central_JJ application_NN of_IN clozapine_NN ._. One_CD problem_NN in_IN delivering_VBG
        substances_NNS centrally_RB is_VBZ the_DT possibility_NN that_IN peripheral_JJ
        spread_NN may_MD confound_NN the_DT results_NNS ._. Since_IN clozapine_NN crosses_VBZ
        the_DT blood-brain_JJ barrier_NN readily_RB [_NN 14_CD ]_NN ,_, the_DT maximum_NN dose_NN
        selected_VBN in_IN the_DT present_JJ experiment_NN was_VBD restricted_VBN to_TO the_DT
        first_JJ appearance_NN of_IN a_DT decrease_NN in_IN blood_NN pressure_NN as_IN an_DT
        indication_NN of_IN possible_JJ peripheral_JJ alpha_NN 1_CD antagonism_NN due_JJ to_TO
        peripheral_JJ leakage_NN ._. We_PRP compared_VBD the_DT effects_NNS obtained_VBN in_IN the_DT
        present_JJ study_NN against_IN those_DT observed_VBN previously_RB after_IN
        intravenous_JJ administration_NN [_NN 12_CD ]_NN expecting_VBG that_IN central_JJ
        effects_NNS would_MD require_VB significantly_RB less_JJR application_NN of_IN
        clozapine_NN than_IN systemic_JJ administration_NN ._. We_PRP considered_VBD a_DT
        minimum_JJ difference_NN of_IN 10_CD ×_NN magnitude_NN in_IN the_DT central_JJ vs_NNS ._.
        peripheral_JJ dose_NN that_IN elicited_JJ a_DT significant_JJ effect_NN as_IN an_DT
        indication_NN of_IN possible_JJ central_JJ action_NN ._. Our_PRP$ doses_NNS of_IN 0_CD ._. 5_CD ,_, 5_CD
        and_CC 50_CD nmoles_NNS of_IN clozapine_NN correspond_VB to_TO serum_NN levels_NNS of_IN 8_CD ,_,
        80_CD and_CC 800_CD ng_NN /_NN ml_NN (_( assuming_VBG a_DT blood_NN volume_NN of_IN 8_CD %_NN of_IN body_NN
        weight_NN )_) and_CC are_VBP in_IN the_DT range_NN of_IN therapeutic_JJ levels_NNS (_( 260_CD -_: 387_CD
        ng_NN /_NN ml_NN [_NN 5_CD 15_CD ]_NN )_) ._.
        A_DT second_JJ problem_NN in_IN administering_VBG a_DT substance_NN at_IN a_DT
        particular_JJ central_JJ location_NN is_VBZ that_IN of_IN redistribution_NN to_TO
        other_JJ parts_NNS of_IN the_DT central_JJ nervous_JJ system_NN ._. Since_IN
        application_NN of_IN a_DT substance_NN at_IN the_DT lumbosacral_NN spinal_JJ level_NN
        may_MD travel_VB to_TO the_DT brain_NN after_IN some_DT time_NN and_CC vice_NN versa_RB ,_, we_PRP
        established_VBD two_CD criteria_NNS to_TO help_VB determine_VB a_DT possible_JJ
        central_JJ site_NN of_IN action_NN :_: 1_LS )_) the_DT first_JJ dose_NN to_TO elicit_NN a_DT
        significant_JJ effect_NN by_IN either_DT i_NNP ._. t_NN ._. or_CC i_NNP ._. c_SYM ._. v_NN administration_NN ;_:
        2_LS )_) significant_JJ differences_NNS at_IN the_DT same_JJ dose_NN but_CC different_JJ
        routes_NNS (_( i_NNP ._. t_NN ._. vs_NNS i_NNP ._. c_SYM ._. v_NN )_) ._.
        Figure_NN 7_CD is_VBZ a_DT summary_NN of_IN our_PRP$ findings_NNS when_WRB interpreted_VBN in_IN
        light_NN of_IN the_DT criteria_NNS stated_VBN above_IN for_IN determining_VBG (_( a_DT )_)
        central_JJ vs_NNS peripheral_JJ effects_NNS and_CC (_( b_SYM )_) spinal_JJ vs_NNS supraspinal_NN
        site_NN of_IN action_NN ._. The_DT effects_NNS are_VBP presented_VBN as_IN percent_NN change_NN
        over_IN the_DT control_NN (_( vehicle_NN )_) dose_NN ,_, for_IN each_DT of_IN the_DT central_JJ
        routes_NNS in_IN the_DT present_JJ experiment_NN and_CC our_PRP$ previously_RB
        reported_VBD findings_NNS for_IN systemic_JJ administration_NN [_NN 12_CD ]_NN ._.
        Theses_NNP changes_NNS are_VBP plotted_VBD at_IN the_DT dose_NN (_( mg_NN /_NN kg_NN )_) that_IN first_RB
        yielded_VBD significant_JJ results_NNS ._. The_DT route_NN that_IN we_PRP consider_VBP
        most_RBS likely_JJ to_TO be_VB the_DT site_NN of_IN action_NN for_IN clozapine_NN is_VBZ
        italicized_JJ ._.
        Bladder_NNP capacity_NN was_VBD increased_VBN to_TO a_DT similar_JJ degree_NN by_IN an_DT
        equivalent_NN dose_NN of_IN clozapine_NN ,_, regardless_RB of_IN route_NN (_( Fig_NNP 7_CD A_DT ;_:
        3_CD A_DT )_) ,_, making_VBG a_DT determination_NN of_IN most_JJS likely_JJ site_NN of_IN action_NN
        difficult_JJ ._. Given_VBN that_IN the_DT peripheral_JJ effects_NNS at_IN low_JJ doses_NNS
        were_VBD similar_JJ to_TO the_DT effects_NNS after_IN the_DT highest_JJS central_JJ dose_NN
        of_IN clozapine_NN (_( by_IN either_DT route_NN )_) it_PRP appears_VBZ likely_JJ that_IN this_DT
        effect_NN is_VBZ due_JJ to_TO peripheral_JJ actions_NNS of_IN clozapine_NN ._. Bladder_NNP
        capacity_NN was_VBD reported_VBN to_TO increase_VB following_VBG i_NNP ._. c_SYM ._. v_NN ._.
        administration_NN of_IN muscarinic_JJ antagonist_NN (_( atropine_NN [_NN 16_CD ]_NN )_)
        or_CC i_NNP ._. t_NN ._. alpha_NN 2_CD antagonists_NNS (_( yohimbine_NN [_NN 17_CD ]_NN ;_: atipemazole_NN
        [_NN 18_CD ]_NN )_) ._. Given_VBN clozapine_NN 's_POS strong_JJ affinity_NN for_IN muscarinic_JJ
        and_CC alpha_NN 2_CD receptors_NNS [_NN 2_CD ]_NN it_PRP is_VBZ possible_JJ that_IN central_JJ
        effects_NNS are_VBP also_RB contributing_VBG to_TO the_DT increase_NN in_IN bladder_NN
        capacity_NN ._.
        Micturition_NNP volume_NN ,_, on_IN the_DT other_JJ hand_NN ,_, showed_VBD a_DT
        reduction_NN after_IN smaller_JJR doses_NNS of_IN clozapine_NN i_NNP ._. c_SYM ._. v_NN or_CC i_NNP ._. t_NN ._.
        when_WRB compared_VBN to_TO the_DT i_NNP ._. v_NN ._. dose_NN (_( Fig_NNP 7_CD B_NNP ;_: 3_CD B_NNP )_) ._. Therefore_RB ,_,
        central_JJ effects_NNS of_IN clozapine_NN in_IN controlling_VBG micturition_NN
        volume_NN are_VBP likely_JJ ._. Furthermore_RB ,_, when_WRB comparing_VBG the_DT effects_NNS
        of_IN i_NNP ._. t_NN ._. vs_NNS ._. i_NNP ._. c_SYM ._. v_NN administration_NN ,_, a_DT 5_CD nmoles_NNS dose_NN of_IN
        clozapine_NN i_NNP ._. c_SYM ._. v_NN ._. elicited_JJ a_DT reduction_NN in_IN micturition_NN volume_NN
        that_WDT was_VBD significantly_RB greater_JJR from_IN the_DT effects_NNS observed_VBD
        after_IN the_DT same_JJ dose_NN i_NNP ._. t_NN ._. (_( Fig_NNP ._. 3_LS B_NNP )_) ._. Therefore_RB ,_, supraspinal_NN
        effects_NNS of_IN clozapine_NN in_IN regulating_VBG micturition_NN volume_NN are_VBP
        likely_JJ with_IN spinal_JJ effects_NNS perhaps_RB contributing_VBG ._. Clozapine_NNP
        i_NNP ._. t_NN ._. also_RB decreased_VBD the_DT micturition_NN volume_NN ,_, however_RB the_DT
        dose_NN that_IN first_RB showed_VBD a_DT significant_JJ effect_NN was_VBD higher_JJR than_IN
        the_DT i_NNP ._. c_SYM ._. v_NN ._. but_CC smaller_JJR than_IN the_DT i_NNP ._. v_NN ._. dose_NN ._. Spinal_NNP
        antagonism_NN of_IN either_DT alpha_NN 1_CD or_CC alpha_NN 2_CD adrenergic_JJ receptors_NNS
        was_VBD reported_VBN to_TO increase_VB micturition_NN volume_NN [_NN 17_CD ]_NN in_IN
        anesthetized_JJ rats_NNS ._. However_RB ,_, intrathecal_NN atipamezole_NN (_( alpha_NN 2_CD
        antagonist_NN )_) increased_VBN residual_JJ volume_NN in_IN awake_JJ rats_NNS [_NN 18_CD ]_NN
        ._. Therefore_RB ,_, it_PRP is_VBZ difficult_JJ to_TO interpret_VB clozapine_NN 's_POS
        effects_NNS on_IN micturition_NN volume_NN in_IN terms_NNS of_IN spinal_JJ alpha_NN
        adrenoceptor_NN antagonism_NN and_CC possibly_RB the_DT supraspinal_NN
        effects_NNS predominate_NN ._.
        Clozapine_NNP given_VBN i_NNP ._. t_NN ._. or_CC i_NNP ._. c_SYM ._. v_NN ._. also_RB increased_VBD the_DT
        residual_JJ volume_NN (_( Fig_NNP 7_CD C_NNP ;_: 3_CD C_NNP )_) ._. Since_IN the_DT effects_NNS were_VBD
        observed_VBN at_IN doses_NNS that_WDT were_VBD lower_JJR than_IN those_DT after_IN i_NNP ._. v_NN ._.
        administration_NN ,_, a_DT peripheral_JJ effect_NN of_IN clozapine_NN to_TO
        increase_VB residual_JJ volume_NN appears_VBZ unlikely_JJ ._. The_DT smallest_JJS
        dose_NN of_IN clozapine_NN given_VBN i_NNP ._. c_SYM ._. v_NN ._. (_( 0_CD ._. 5_LS nmoles_NNS )_) increased_VBN
        residual_JJ volume_NN to_TO 160_CD %_NN (_( Fig_NNP 7_CD C_NNP )_) ,_, suggesting_VBG that_IN
        supraspinal_NN effects_NNS predominate_NN with_IN possible_JJ contributing_VBG
        effects_NNS from_IN spinal_JJ sites_NNS ._. Ishiura_NNP et_CC al_NN ._. [_NN 16_CD ]_NN reported_VBD a_DT
        decrease_NN in_IN voiding_VBG efficiency_NN (_( comparable_JJ to_TO an_DT increase_NN
        in_IN residual_JJ volume_NN )_) following_VBG atropine_NN i_NNP ._. c_SYM ._. v_NN ._. or_CC i_NNP ._. t_NN ._.
        suggesting_VBG that_IN muscarinic_JJ receptors_NNS at_IN supraspinal_NN and_CC
        spinal_JJ sites_NNS are_VBP involved_VBN and_CC may_MD account_VB for_IN our_PRP$ effects_NNS
        after_IN clozapine_NN i_NNP ._. t_NN ._. or_CC i_NNP ._. c_SYM ._. v_NN ._. A_DT decrease_NN in_IN residual_JJ
        volume_NN has_VBZ been_VBN reported_VBN following_VBG spinal_JJ antagonism_NN of_IN
        alpha_NN 2_CD receptors_NNS with_IN yohimbine_NN [_NN 17_CD ]_NN but_CC atipamezole_NN
        produced_VBD an_DT increase_NN in_IN the_DT residual_JJ volume_NN [_NN 18_CD ]_NN ,_,
        similar_JJ to_TO our_PRP$ findings_NNS with_IN clozapine_NN i_NNP ._. t_NN ._.
        Clozapine_NNP increased_VBD pressure_NN threshold_NN after_IN i_NNP ._. c_SYM ._. v_NN ._. or_CC
        i_NNP ._. t_NN ._. administration_NN only_RB after_IN 50_CD nmoles_NNS (_( Fig_NNP 7_CD D_NNP ;_: 4_CD A_DT )_) ._. It_PRP
        should_MD be_VB noted_VBN that_IN both_DT central_JJ doses_NNS were_VBD at_IN the_DT range_NN
        observed_VBD to_TO result_VB in_IN cardiovascular_JJ changes_NNS and_CC therefore_RB
        the_DT possibility_NN of_IN peripheral_JJ leakage_NN of_IN clozapine_NN must_MD be_VB
        considered_VBN ._. Still_RB the_DT effective_JJ central_JJ doses_NNS are_VBP
        approximately_RB 14_CD ×_NN less_JJR than_IN the_DT first_JJ dose_NN observed_VBD to_TO
        produce_VB significant_JJ results_NNS intravenously_RB ,_, and_CC suggests_VBZ a_DT
        possible_JJ central_JJ site_NN of_IN action_NN ._.
        Peak_NNP pressure_NN was_VBD not_RB changed_JJ by_IN clozapine_NN after_IN either_DT
        route_NN in_IN the_DT present_JJ study_NN after_IN central_JJ administration_NN ,_,
        consistent_JJ with_IN our_PRP$ findings_NNS afer_NN intravenous_JJ
        administration_NN [_NN 12_CD ]_NN ._. Ishiura_NNP et_CC al_NN ._. [_NN 16_CD ]_NN reported_VBD a_DT
        decrease_NN in_IN maximal_NN voiding_VBG pressure_NN (_( equivalent_JJ to_TO our_PRP$
        peak_NN pressure_NN )_) after_IN atropine_NN i_NNP ._. v_NN ._. ,_, i_NNP ._. c_SYM ._. v_NN or_CC i_NNP ._. t_NN ._. in_IN awake_JJ
        rats_NNS undergoing_VBG continuous_JJ cystometry_NN ._. Given_VBN that_DT clozapine_NN
        has_VBZ a_DT relatively_RB high_JJ affinity_NN for_IN muscarinic_JJ receptors_NNS [_NN 1_CD
        2_CD ]_NN it_PRP is_VBZ surprising_JJ that_IN we_PRP have_VBP not_RB seen_VBN an_DT effect_NN on_IN
        peak_NN pressure_NN ._. Clozapine_NNP ,_, and_CC also_RB olanzapine_NN [_NN 11_CD 13_CD ]_NN
        were_VBD able_JJ to_TO decrease_VB the_DT contraction_NN amplitude_NN after_IN
        electrical_JJ stimulation_NN of_IN the_DT pelvic_JJ nerve_NN ._. Since_IN the_DT
        contraction_NN pressures_NNS observed_VBD during_IN cystometry_NN were_VBD
        smaller_JJR than_IN those_DT observed_VBN after_IN electrical_JJ stimulation_NN of_IN
        the_DT pelvic_JJ nerve_NN (_( and_CC against_IN a_DT closed_VBN urethra_NN )_) it_PRP is_VBZ
        possible_JJ that_IN the_DT antimuscarinic_JJ effects_NNS of_IN clozapine_NN on_IN
        bladder_NN contraction_NN pressure_NN are_VBP not_RB detected_VBN because_IN
        during_IN cystometry_NN maximal_NN bladder_NN pressures_NNS are_VBP not_RB
        necessary_JJ for_IN emptying_VBG ._.
        Contraction_NNP time_NN was_VBD not_RB affected_VBN by_IN clozapine_NN i_NNP ._. c_SYM ._. v_NN or_CC
        i_NNP ._. t_NN ._. (_( Table_NNP 1_CD and_CC 2_CD ;_: Fig_NNP 5_CD A_DT )_) however_RB it_PRP was_VBD clearly_RB
        decreased_VBN after_IN intravenous_JJ administration_NN [_NN 12_CD ]_NN ._.
        Therefore_RB ,_, we_PRP suspect_VBP that_IN solely_RB peripheral_JJ effects_NNS may_MD
        explain_VB the_DT effects_NNS of_IN clozapine_NN on_IN contraction_NN time_NN ._.
        Antimuscarinic_NNP agents_NNS have_VBP been_VBN show_NN to_TO decrease_VB
        contraction_NN time_NN (_( e_SYM ._. g_SYM ._. atropine_NN [_NN 19_CD ]_NN )_) and_CC since_IN
        clozapine_NN has_VBZ high_JJ affinity_NN for_IN muscarinic_JJ receptors_NNS it_PRP is_VBZ
        likely_JJ that_IN peripheral_JJ anti-muscarinic_JJ effects_NNS of_IN clozapine_NN
        are_VBP responsible_JJ for_IN the_DT reduction_NN in_IN contraction_NN time_NN after_IN
        systemic_JJ administration_NN ._.
        Expulsion_NNP time_NN was_VBD reduced_VBN by_IN clozapine_NN after_IN i_NNP ._. t_NN ._. or_CC
        i_NNP ._. c_SYM ._. v_NN ._. administration_NN at_IN much_RB smaller_JJR doses_NNS than_IN were_VBD
        observed_VBN to_TO produce_VB similar_JJ results_NNS i_NNP ._. v_NN ._. (_( Fig_NNP 7_CD E_NNP ;_: 5_CD B_NNP )_) ._.
        Therefore_RB ,_, central_JJ effects_NNS of_IN clozapine_NN are_VBP likely_JJ
        responsible_JJ for_IN the_DT reduction_NN in_IN expulsion_NN time_NN ._. Since_IN the_DT
        intrathecal_NN effects_NNS were_VBD greater_JJR than_IN those_DT observed_VBN after_IN
        i_NNP ._. c_SYM ._. v_NN ._. administration_NN it_PRP is_VBZ possible_JJ that_IN a_DT spinal_JJ action_NN
        predominates_NNS with_IN possible_JJ contribution_NN from_IN supraspinal_NN
        sites_NNS ._.
        The_DT amplitude_NN of_IN the_DT high_JJ frequency_NN oscillations_NNS
        observed_VBD during_IN the_DT expulsion_NN time_NN in_IN the_DT rat_NN micturition_NN
        cycle_NN [_NN 20_CD 21_CD ]_NN was_VBD reduced_VBN by_IN clozapine_NN i_NNP ._. t_NN ._. at_IN a_DT dose_NN of_IN
        5_CD nmoles_NNS (_( Fig_NNP 8_CD F_NN )_) ._. This_DT dose_NN was_VBD 10_CD ×_NN smaller_JJR than_IN the_DT first_JJ
        i_NNP ._. c_SYM ._. v_NN ._. dose_NN observed_VBD to_TO have_VB a_DT significant_JJ effect_NN and_CC
        approximately_RB 142_CD ×_NN smaller_JJR than_IN the_DT first_JJ i_NNP ._. v_NN ._. dose_NN to_TO show_VB
        a_DT significant_JJ effect_NN ._. Therefore_RB ,_, a_DT spinal_JJ site_NN mediating_VBG
        the_DT effects_NNS of_IN clozapine_NN on_IN the_DT amplitude_NN of_IN high_JJ frequency_NN
        oscillations_NNS appears_VBZ likely_JJ ._. Previous_JJ results_NNS [_NN 12_CD ]_NN
        suggest_VBP that_IN D_NNP 2_CD receptors_NNS modulate_VBP the_DT amplitude_NN of_IN the_DT
        HFO_NNP ,_, since_IN raclopride_NN (_( selective_JJ D_NNP 2_CD antagonist_NN )_) decreased_VBD
        the_DT amplitude_NN of_IN the_DT HFO_NNP by_IN 30_CD %_NN ._.
        In_IN addition_NN to_TO clozapine_NN 's_POS effects_NNS on_IN urodynamic_JJ
        parameters_NNS ,_, the_DT EMG_NNP recorded_VBD from_IN the_DT external_JJ urethral_NN
        sphincter_NN also_RB showed_VBD changes_NNS after_IN clozapine_NN i_NNP ._. t_NN ._. or_CC
        i_NNP ._. c_SYM ._. v_NN ._. The_DT EMG_NNP during_IN phase_NN 1_CD of_IN the_DT contraction_NN only_RB
        showed_VBD a_DT reduction_NN after_IN the_DT largest_JJS dose_NN of_IN clozapine_NN
        i_NNP ._. c_SYM ._. v_NN ._. ._. This_DT dose_NN is_VBZ equivalent_JJ to_TO our_PRP$ lowest_JJS dose_NN i_NNP ._. v_NN ._. and_CC
        in_IN fact_NN all_DT doses_NNS i_NNP ._. v_NN ._. previously_RB showed_VBD a_DT significant_JJ
        reduction_NN [_NN 11_CD ]_NN ._. Intrathecal_NNP administration_NN had_VBD no_DT effect_NN
        on_IN the_DT EMG_NNP at_IN phase_NN 1_CD ._.
        The_DT EMG_NNP during_IN phase_NN 2_CD ,_, corresponding_JJ to_TO the_DT period_NN of_IN
        high_JJ frequency_NN oscillations_NNS was_VBD decreased_VBN by_IN clozapine_NN
        after_IN i_NNP ._. t_NN ._. or_CC i_NNP ._. c_SYM ._. v_NN administration_NN at_IN doses_NNS that_WDT were_VBD much_RB
        lower_JJR than_IN those_DT necessary_JJ to_TO produce_VB an_DT effect_NN after_IN i_NNP ._. v_NN ._.
        Therefore_RB ,_, the_DT effects_NNS of_IN clozapine_NN in_IN reducing_VBG the_DT EMG_NNP
        during_IN this_DT phase_NN appear_VBP to_TO be_VB central_JJ in_IN origin_NN ._. Since_IN the_DT
        first_JJ significant_JJ effect_NN was_VBD obtained_VBN after_IN i_NNP ._. c_SYM ._. v_NN ._.
        administration_NN (_( Fig_NNP 7_CD H_NNP )_) it_PRP is_VBZ possible_JJ that_IN supraspinal_NN
        effects_NNS predominate_NN with_IN spinal_JJ sites_NNS contributing_VBG ._.
        The_DT EMG_NNP during_IN phase_NN 3_CD (_( closing_NN phase_NN )_) of_IN the_DT
        contraction_NN was_VBD decreased_VBN only_RB after_IN the_DT highest_JJS dose_NN of_IN
        clozapine_NN (_( 50_CD nmoles_NNS )_) i_NNP ._. c_SYM ._. v_NN ._. (_( Fig_NNP 6_CD C_NNP )_) ._. This_DT dose_NN was_VBD still_RB
        14_CD ×_NN smaller_JJR than_IN the_DT first_JJ significant_JJ dose_NN i_NNP ._. v_NN ._. and_CC
        therefore_RB a_DT central_JJ effect_NN of_IN clozapine_NN is_VBZ probable_JJ ._.
        Finally_RB ,_, the_DT amplitude_NN of_IN the_DT individual_JJ bursts_NNS of_IN EMG_NNP
        recorded_VBD from_IN the_DT external_JJ urethral_NN sphincter_NN during_IN phase_NN
        2_CD of_IN the_DT contraction_NN also_RB decreased_VBD after_IN clozapine_NN i_NNP ._. t_NN ._. or_CC
        i_NNP ._. c_SYM ._. v_NN ._. (_( Fig_NNP 6_CD D_NNP )_) ._. Since_IN the_DT doses_NNS that_WDT yielded_VBD significant_JJ
        reductions_NNS were_VBD smaller_JJR than_IN those_DT observed_VBN after_IN i_NNP ._. v_NN ._.
        admnistration_NN ,_, a_DT central_JJ effect_NN is_VBZ likely_JJ ._. Moreover_RB ,_, since_IN
        5_CD nmoles_NNS of_IN clozapine_NN i_NNP ._. t_NN ._. produced_VBD a_DT significant_JJ reduction_NN
        when_WRB compared_VBN to_TO the_DT same_JJ dose_NN i_NNP ._. c_SYM ._. v_NN ._. ,_, a_DT spinal_JJ effect_NN of_IN
        clozapine_NN in_IN mediating_VBG the_DT reduction_NN of_IN the_DT burst_NN amplitude_NN
        of_IN the_DT EMG_NNP is_VBZ possible_JJ ._.
        In_IN the_DT anesthetized_JJ rat_NN ,_, the_DT external_JJ urethral_NN sphincter_NN
        contracts_NNS and_CC relaxes_NNS during_IN the_DT expulsion_NN phase_NN in_IN a_DT
        manner_NN that_WDT is_VBZ complimentary_JJ to_TO the_DT high_JJ frequency_NN
        oscillations_NNS observed_VBD in_IN the_DT bladder_NN pressure_NN record_NN [_NN 19_CD ]_NN
        whereas_IN in_IN humans_NNS the_DT external_JJ sphincter_NN not_RB active_JJ during_IN
        voiding_VBG ._. Pharmacological_NNP blockade_NN of_IN the_DT external_JJ urethral_NN
        sphincter_NN in_IN the_DT rat_NN resulted_VBD in_IN decreased_VBD micturition_NN
        volume_NN and_CC increased_VBN residual_JJ volume_NN [_NN 20_CD 21_CD 22_CD 23_CD ]_NN
        suggesting_VBG that_IN the_DT activity_NN of_IN the_DT external_JJ urethral_NN
        sphincter_NN contributes_VBZ to_TO efficient_JJ voiding_VBG in_IN the_DT rat_NN ._.
        Therefore_RB ,_, central_JJ administration_NN of_IN clozapine_NN ,_, by_IN reducing_VBG
        the_DT activity_NN of_IN the_DT EUS_NNP ,_, contributes_VBZ to_TO the_DT decrease_NN in_IN
        voiding_VBG efficiency_NN by_IN reducing_VBG micturition_NN volume_NN and_CC
        increasing_VBG residual_JJ volume_NN ._.
        Alpha_NNP 1_CD adrenergic_JJ antagonists_NNS have_VBP been_VBN shown_VBN to_TO inhibit_VB
        pudendal_NN reflexes_NNS in_IN anesthetized_JJ cats_NNS [_NN 24_CD 25_CD 26_CD ]_NN ._.
        However_RB ,_, a_DT systemic_JJ dose_NN of_IN prazosin_NN (_( alpha_NN 1_CD antagonist_NN )_)
        did_VBD not_RB inhibit_VB the_DT EUS_NNP EMG_NNP activity_NN during_IN high_JJ frequency_NN
        oscillations_NNS in_IN the_DT rat_NN [_NN 27_CD ]_NN ._. Thus_RB ,_, although_IN alpha_NN 1_CD
        antagonism_NN has_VBZ been_VBN shown_VBN to_TO modulate_VBP pudendal_NN reflexes_NNS in_IN
        the_DT cat_NN ,_, their_PRP$ role_NN in_IN modulating_VBG the_DT activity_NN of_IN the_DT EUS_NNP
        during_IN micturition_NN in_IN the_DT rat_NN appears_VBZ unclear_JJ ._.
        In_IN summary_NN ,_, our_PRP$ results_NNS in_IN the_DT present_JJ experiments_NNS
        suggest_VBP that_IN most_JJS of_IN the_DT effects_NNS of_IN clozapine_NN on_IN urodynamic_JJ
        parameters_NNS can_MD be_VB ascribed_VBN to_TO central_JJ effects_NNS ._. Expulsion_NNP
        parameters_NNS ,_, such_JJ as_IN micturition_NN volume_NN ,_, residual_JJ volume_NN ,_,
        expulsion_NN time_NN ,_, and_CC amplitude_NN of_IN the_DT high-frequency_JJ
        oscillations_NNS ,_, appear_VB to_TO be_VB mediated_JJ by_IN the_DT central_JJ action_NN
        (_( spinal_NN or_CC supraspinal_NN )_) of_IN clozapine_NN ._. The_DT activity_NN of_IN the_DT
        EUS_NNP also_RB appears_VBZ to_TO decrease_VB after_IN central_JJ application_NN of_IN
        clozapine_NN ._. Therefore_RB ,_, central_JJ effects_NNS of_IN clozapine_NN appear_VBP
        to_TO decrease_VB the_DT voiding_VBG efficiency_NN of_IN the_DT bladder_NN in_IN the_DT
        rat_NN ._. Contraction_NNP time_NN clearly_RB showed_VBD a_DT peripheral_JJ effect_NN
        only_RB ,_, whereas_IN changes_NNS in_IN bladder_NN capacity_NN were_VBD difficult_JJ to_TO
        explain_VB from_IN central_JJ effects_NNS and_CC probably_RB reflect_VB
        peripheral_JJ effects_NNS of_IN clozapine_NN ._.
        Clozapine_NNP is_VBZ metabolized_VBN mainly_RB at_IN the_DT liver_NN resulting_VBG
        in_IN several_JJ metabolites_NNS [_NN 5_CD 14_CD ]_NN ._. One_CD of_IN the_DT major_JJ
        metabolites_NNS ,_, N-_NNP desmethylclozapine_NN has_VBZ been_VBN shown_VBN to_TO have_VB
        pharmacological_JJ activity_NN both_DT in_IN vitro_NN [_NN 28_CD ]_NN and_CC in_IN vivo_NN
        in_IN rats_NNS [_NN 29_CD ]_NN ._. In_IN addition_NN ,_, N-_NNP desmethylclozapine_NN is_VBZ found_VBN
        in_IN large_JJ concentrations_NNS in_IN the_DT serum_NN of_IN schizophrenic_JJ
        patients_NNS [_NN 5_CD 15_CD ]_NN and_CC in_IN rats_NNS [_NN 30_CD ]_NN ._. The_DT contribution_NN of_IN
        N-_NNP desmethylclozapine_NN to_TO clozapine_NN 's_POS central_JJ effects_NNS has_VBZ
        been_VBN questioned_VBN recently_RB ,_, since_IN the_DT levels_NNS of_IN
        N-_NNP desmethylclozapine_NN in_IN the_DT brain_NN were_VBD much_RB lower_JJR than_IN
        those_DT of_IN clozapine_NN [_NN 30_CD ]_NN suggesting_VBG that_IN
        N-_NNP desmethylclozapine_NN does_VBZ not_RB cross_VB the_DT blood-brain_JJ barrier_NN
        as_RB readily_RB as_IN clozapine_NN ._. Since_IN we_PRP observed_VBD effects_NNS from_IN
        central_JJ application_NN of_IN clozapine_NN ,_, we_PRP consider_VBP it_PRP unlikely_JJ
        that_IN the_DT effects_NNS of_IN metabolites_NNS contributed_VBD significantly_RB ._.
        However_RB ,_, whether_IN any_DT of_IN the_DT major_JJ clozapine_NN metabolites_NNS
        also_RB have_VBP a_DT role_NN in_IN regulating_VBG micturition_NN remains_VBZ to_TO be_VB
        determined_VBN ._.
      
      
        Conclusions_NNP
        Atypical_NNP neuroleptics_NNS are_VBP useful_JJ in_IN treating_VBG patients_NNS
        that_WDT are_VBP refractory_JJ to_TO "_'' traditional_JJ "_'' antipsychotic_JJ
        medication_NN and_CC produce_VB fewer_JJR extrapyramidal_NN side_NN effects_NNS ._.
        However_RB ,_, other_JJ side_NN effects_NNS still_RB occur_VBP with_IN varying_VBG
        severity_NN and_CC frequency_NN [_NN 31_CD ]_NN and_CC continue_VB to_TO pose_VB a_DT
        challenge_NN to_TO effective_JJ treatment_NN ._. Urinary_NNP disturbances_NNS as_IN a_DT
        result_NN of_IN clozapine_NN therapy_NN have_VBP been_VBN well_RB documented_VBN ,_, and_CC
        include_VBP incontinence_NN ,_, enuresis_NNS and_CC urgency_NN [_NN 4_CD 5_CD 32_CD ]_NN ._.
        Other_JJ atypical_JJ antipsychotics_NNS ,_, such_JJ as_IN risperidone_NN [_NN 7_CD ]_NN
        and_CC olanzapine_NN [_NN 10_CD ]_NN have_VBP been_VBN reported_VBN to_TO produce_VB urinary_JJ
        incontinence_NN ._.
        We_PRP have_VBP previously_RB shown_VBN [_NN 11_CD 12_CD 13_CD ]_NN that_IN systemic_JJ
        administration_NN of_IN clozapine_NN ,_, olanzapine_NN and_CC risperidone_NN to_TO
        anesthetized_JJ rats_NNS reduced_VBD voiding_VBG efficiency_NN ._. Risperidone_NNP
        had_VBD smaller_JJR maximal_NN effects_NNS than_IN olanzapine_NN and_CC clozapine_NN
        and_CC had_VBD no_DT direct_JJ (_( peripheral_JJ )_) inhibitory_NN effects_NNS on_IN the_DT
        amplitude_NN of_IN bladder_NN contractions_NNS ._. In_IN the_DT present_JJ study_NN we_PRP
        show_VBP that_IN clozapine_NN acts_NNS at_IN supraspinal_NN and_CC spinal_JJ sites_NNS to_TO
        inhibit_VB certain_JJ urodynamic_JJ parameters_NNS and_CC the_DT external_JJ
        urethral_NN sphincter_NN of_IN the_DT rat_NN resulting_VBG in_IN decreased_VBD
        voiding_VBG efficiency_NN ._.
        If_IN these_DT effects_NNS also_RB occur_VBP in_IN patients_NNS ,_, they_PRP may_MD
        contribute_VB to_TO the_DT urinary_JJ disturbances_NNS reported_VBD following_VBG
        clozapine_NN therapy_NN ._. The_DT exact_JJ receptor_NN types_NNS (_( or_CC combination_NN
        of_IN receptor_NN types_NNS )_) responsible_JJ for_IN clozapine_NN 's_POS central_JJ
        effects_NNS on_IN micturition_NN were_VBD not_RB investigated_VBN in_IN the_DT present_JJ
        study_NN ._. However_RB ,_, isolating_VBG particular_JJ receptors_NNS that_WDT
        contribute_VBP to_TO the_DT effects_NNS of_IN clozapine_NN might_MD be_VB useful_JJ in_IN
        designing_VBG neuroleptics_NNS that_WDT may_MD avoid_VB these_DT side_NN effects_NNS or_CC
        in_IN providing_VBG an_DT adjunct_NN therapy_NN to_TO relieve_VB some_DT of_IN the_DT side_NN
        effects_NNS ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Surgical_NNP procedures_NNS
          The_DT experiments_NNS were_VBD conducted_VBN in_IN compliance_NN with_IN the_DT
          USDA_NNP Animal_NNP Welfare_NNP Act_NNP and_CC amendments_NNS thereto_NN and_CC the_DT
          revised_VBN Guide_NNP for_IN the_DT Care_NNP and_CC use_NN of_IN Laboratory_NNP Animals_NNPS
          DHEW_NNP (_( NIH_NNP )_) and_CC were_VBD approved_VBN by_IN the_DT Animal_NNP Studies_NNP
          Subcommittee_NNP of_IN the_DT Bay_NNP Pines_NNP Veterans_NNP Administration_NNP
          Medical_NNP Center_NNP ._.
          Surgical_NNP procedures_NNS have_VBP been_VBN described_VBN in_IN detail_NN
          elsewhere_RB [_NN 12_CD ]_NN ._. Rats_NNP (_( female_JJ Sprague-_NNP Dawley_NNP ;_: n_NN =_SYM 16_CD ;_:
          230_CD -_: 270_CD g_SYM ;_: Harlan_NNP ;_: IN_IN )_) were_VBD anesthetized_JJ with_IN halothane_NN
          and_CC placed_VBN on_IN a_DT heating_NN pad_NN ._. A_DT catheter_NN (_( PE-_NNP 50_CD )_) was_VBD
          introduced_VBN into_IN the_DT jugular_NN vein_NN to_TO administer_VB urethane_NN
          (_( 1_CD ._. 1_LS g_SYM /_NN kg_NN )_) over_IN a_DT period_NN of_IN 20_CD minutes_NNS while_IN decreasing_VBG
          the_DT level_NN of_IN halothane_NN to_TO prevent_VB respiratory_JJ depression_NN ._.
          Rats_NNP were_VBD instrumented_JJ with_IN either_DT an_DT intrathecal_NN cannula_NN
          placed_VBN over_IN the_DT L_NNP 6_CD /_NN S_NNP 1_CD spinal_JJ segment_NN or_CC a_DT cannula_NN into_IN
          the_DT right_JJ lateral_NN ventricle_NN ._.
          An_DT incision_NN was_VBD made_VBN over_IN the_DT dorsal_NN aspect_NN of_IN the_DT
          neck_NN and_CC the_DT overlying_VBG muscles_NNS were_VBD retracted_VBD to_TO expose_VB
          the_DT atlanto-occipital_JJ membrane_NN ._. An_DT intrathecal_NN catheter_NN
          (_( PE_NNP 10_CD )_) was_VBD introduced_VBN through_IN a_DT small_JJ slit_NN in_IN the_DT
          atlanto-occipital_JJ membrane_NN and_CC positioned_VBN over_IN the_DT L_NNP 6_CD /_NN S_NNP 1_CD
          spinal_JJ cord_NN segments_NNS [_NN 33_CD ]_NN ._. Saline_NNP soaked_JJ gelfoam_NN was_VBD
          placed_VBN around_IN the_DT catheter_NN and_CC the_DT neck_NN muscles_NNS and_CC skin_NN
          were_VBD sutured_JJ ._. Spinal_NNP segmental_NN location_NN of_IN the_DT catheter_NN
          was_VBD verified_VBN post-mortem_JJ by_IN performing_VBG a_DT laminectomy_NN ._.
          Following_VBG a_DT small_JJ craniectomy_NN ,_, a_DT stainless-steel_JJ
          cannula_NN (_( 27_CD ga_NN )_) was_VBD placed_VBN in_IN the_DT lateral_NN ventricle_NN at_IN
          the_DT following_JJ coordinates_VBZ :_: AP_NNP -_: 1_CD ._. 0_CD ,_, ML_NNP =_SYM 1_CD ._. 2_CD ;_: V_NNP =_SYM 3_CD ._. 2_CD mm_NN
          [_NN 34_CD ]_NN ._. The_DT cannula_NN was_VBD held_VBN in_IN place_NN with_IN skull_NN screws_NNS
          and_CC dental_JJ acrylic_JJ ._. At_IN the_DT end_NN of_IN the_DT experiment_NN ,_, 5_CD μl_NN of_IN
          fast-green_JJ (_( 1_CD %_NN )_) was_VBD infused_VBN through_IN the_DT cannula_NN while_IN
          observing_VBG the_DT CSF_NNP though_IN a_DT small_JJ slit_NN in_IN the_DT
          atlanto-occipital_JJ membrane_NN ._. Almost_RB immediate_JJ
          visualization_NN of_IN the_DT fast-green_JJ in_IN the_DT fourth_JJ ventricle_NN
          was_VBD taken_VBN to_TO indicate_VB appropriate_JJ placement_NN of_IN the_DT
          cannula_NN into_IN the_DT lateral_NN ventricle_NN ._.
          After_IN an_DT abdominal_NN incision_NN ,_, both_DT ureters_NNS were_VBD tied_VBN
          distally_RB and_CC cut_VB centrally_RB and_CC allowed_VBN to_TO drain_VB onto_IN
          cotton_NN gauzes_NNS that_WDT were_VBD directed_VBN outside_IN the_DT animal_NN ._. A_DT
          catheter_NN (_( PE-_NNP 90_CD )_) was_VBD introduced_VBN into_IN the_DT bladder_NN dome_NN and_CC
          tied_VBN in_IN place_NN with_IN a_DT purse_NN string_NN suture_NN ._. A_DT catheter_NN
          (_( PE-_NNP 50_CD )_) was_VBD introduced_VBN into_IN the_DT right_JJ femoral_NN artery_NN for_IN
          blood_NN pressure_NN recording_NN ._. Stainless-steel_NNP wires_NNS (_( 0_CD ._. 003_CD
          in_IN ._. ;_: A-M_NNP Systems_NNPS ;_: WA_NNP )_) insulated_VBN except_IN at_IN the_DT tip_NN were_VBD
          introduced_VBN into_IN the_DT external_JJ urethral_NN sphincter_NN for_IN EMG_NNP
          recording_NN (_( DAM_NNP 50_CD ;_: WPI_NNP ;_: bandwidth_NN =_SYM 3_CD to_TO 3_CD kHz_NN ;_: gain_NN :_:
          1000_CD -_: 10_CD ,_, 000_CD )_) ._.
        
        
          Urodynamic_NNP studies_NNS
          In_IN pilot_NN animals_NNS ,_, the_DT dose_NN and_CC duration_NN of_IN effects_NNS was_VBD
          determined_VBN by_IN administering_VBG clozapine_NN (_( saline_NN ,_,
          0_CD ._. 5_CD ,_, 5_CD ,_, 50_CD ,_, 100_CD nmoles_NNS )_) at_IN 10_CD min_NN intervals_NNS either_CC
          intrathecally_RB (_( n_NN =_SYM 2_LS )_) or_CC intracerebroventricularly_RB (_( n_NN =_SYM
          2_LS )_) during_IN continuous_JJ cystometry_NN (_( infusion_NN rate_NN =_SYM 0_CD ._. 11_CD
          ml_NN /_NN min_NN )_) while_IN recording_NN bladder_NN pressure_NN ,_, external_JJ
          urethral_NN sphincter_NN EMG_NNP ,_, and_CC blood_NN pressure_NN ._. Fifty_NNP (_( 50_CD )_)
          nmoles_NNS of_IN clozapine_NN administered_VBN by_IN either_DT route_NN resulted_VBD
          in_IN a_DT decrease_NN in_IN arterial_NN pressure_NN (_( mean_JJ decrease_VB in_IN MAP_NNP
          was_VBD 20_CD ±_NN 2_CD and_CC 15_CD ±_NN 3_CD mm_NN Hg_NNP for_IN intrathecal_NN and_CC
          intracerebroventricular_NN administration_NN ,_, respectively_RB ._. The_DT
          onset_NN time_NN ranged_VBD from_IN 1_CD -_: 1_CD ._. 5_LS min_NN from_IN the_DT start_NN of_IN the_DT
          infusion_NN )_) ._. Since_IN clozapine_NN has_VBZ alpha_NN 1_CD antagonist_NN effects_NNS
          [_NN 2_CD ]_NN it_PRP is_VBZ possible_JJ that_IN the_DT blood_NN pressure_NN decreases_NNS
          were_VBD due_JJ to_TO spread_NN of_IN clozapine_NN into_IN the_DT periphery_NN
          following_VBG central_JJ administration_NN ._. Doses_NNP smaller_JJR than_IN 50_CD
          nmoles_NNS did_VBD not_RB elicit_NN a_DT drop_NN in_IN arterial_NN pressure_NN ._. In_IN
          addition_NN ,_, 50_CD nmoles_NNS represents_VBZ a_DT dose_NN close_RB to_TO the_DT
          smallest_JJS intravenous_JJ dose_NN used_VBN previously_RB (_( 0_CD ._. 1_LS mg_NN /_NN kg_NN [_NN 12_CD
          ]_NN )_) ._. Therefore_RB ,_, during_IN single_JJ cystometry_NN ,_, the_DT dose_NN range_NN
          was_VBD limited_VBN to_TO 0_CD ._. 5_CD to_TO 50_CD nmoles_NNS in_IN order_NN to_TO reduce_VB
          possible_JJ peripheral_JJ spread_NN of_IN clozapine_NN ._.
          Single_NNP cystometry_NN studies_NNS were_VBD conducted_VBN as_IN follows_VBZ ._.
          The_DT bladder_NN was_VBD emptied_VBN and_CC allowed_VBN to_TO equilibrate_NN to_TO air_VB
          pressure_NN for_IN 5_CD minutes_NNS before_IN beginning_VBG each_DT
          cystometrogram_NN ._. Room_NNP temperature_NN saline_NN was_VBD infused_VBN into_IN
          the_DT bladder_NN (_( 0_CD ._. 11_CD ml_NN /_NN min_NN )_) while_IN recording_NN bladder_NN
          pressure_NN and_CC the_DT infusion_NN was_VBD stopped_VBN when_WRB a_DT contraction_NN
          occurred_VBD ._. Volume_NN expelled_VBN was_VBD determined_VBN by_IN placing_VBG
          cotton_NN gauze_NN at_IN the_DT urinary_JJ meatus_JJ and_CC weighing_VBG before_IN
          and_CC after_IN micturition_NN ._. External_NNP urethral_NN sphincter_NN EMG_NNP
          (_( EUS-EMG_NNP )_) was_VBD recorded_VBN throughout_IN the_DT cystometrogram_NN and_CC
          for_IN some_DT time_NN after_IN the_DT filling_VBG had_VBN stopped_VBN ._. Increasing_VBG
          doses_NNS of_IN clozapine_NN (_( Sigma_NNP ,_, vehicle_NN ,_, 0_CD ._. 5_CD ,_, 5_CD ,_, 50_CD nmoles_NNS in_IN
          a_DT volume_NN of_IN 5_CD μl_NN ;_: followed_VBN by_IN a_DT 7_CD μl_NN saline_NN wash_NN )_) were_VBD
          administered_VBN through_IN the_DT intrathecal_NN catheter_NN (_( n_NN =_SYM 6_CD ;_:
          Mean_VB weight_NN =_SYM 245_CD gm_NN )_) or_CC through_IN the_DT
          intracerebroventricular_NN cannula_NN (_( n_NN =_SYM 6_CD ;_: Mean_VB weight_NN =_SYM 245_CD
          gm_NN )_) at_IN approximately_RB 10_CD -_: minute_NN intervals_NNS ._. Clozapine_NNP was_VBD
          dissolved_VBN in_IN a_DT minimal_JJ amount_NN of_IN 0_CD ._. 1_CD N_NNP hydrochloric_JJ acid_NN ,_,
          and_CC brought_VBD up_RP to_TO volume_NN with_IN saline_NN (_( final_JJ pH_NN =_SYM 6_CD )_) ._.
          Cystometrograms_NNP were_VBD started_VBN approximately_RB 3_CD minutes_NNS
          after_IN each_DT drug_NN administration_NN ._. At_IN the_DT end_NN of_IN the_DT
          experiment_NN the_DT rat_NN was_VBD euthanized_JJ with_IN an_DT overdose_NN of_IN
          urethane_NN (_( 3_CD ._. 0_CD mg_NN /_NN kg_NN ;_: i_NNP ._. v_NN ._. )_) ._.
        
        
          Data_NNP analysis_NN
          Bladder_NNP pressure_NN ,_, EUS-EMG_NNP and_CC blood_NN pressure_NN during_IN
          the_DT single_JJ cystometrograms_NNS were_VBD displayed_VBN in_IN an_DT
          electronic_JJ chart_NN recorder_NN (_( RC_NNP Electronics_NNP ;_: Goleta_NNP ,_, CA_NNP )_)
          and_CC analyzed_VBD off-line_JJ (_( Dataview_NNP ,_, W_NNP ._. J_NNP ._. Heitler_NNP ,_, U_NNP ._. St_NNP
          Andrews_NNP ,_, Scotland_NNP )_) ._. The_DT following_VBG parameters_NNS were_VBD
          examined_VBN from_IN the_DT cystometrogram_NN as_IN described_VBN in_IN detail_NN
          earlier_JJR [_NN 12_CD ]_NN :_: bladder_NN capacity_NN (_( amount_NN of_IN fluid_JJ
          infused_VBN to_TO elicit_NN a_DT contraction_NN )_) ;_: micturition_NN volume_NN
          (_( amount_NN of_IN fluid_JJ expelled_VBN )_) ;_: residual_JJ volume_NN (_( [_NN bladder_NN
          capacity-micturition_JJ volume_NN ]_NN /_NN [_NN bladder_NN capacity_NN ]_NN ×_NN 100_CD )_) ;_:
          pressure_NN threshold_NN (_( pressure_NN at_IN which_WDT contraction_NN
          begins_VBZ )_) ;_: peak_NN pressure_NN (_( maximal_NN pressure_NN during_IN
          contraction_NN )_) ;_: contraction_NN time_NN ;_: expulsion_NN time_NN (_( time_NN
          between_IN peak_NN pressure_NN and_CC end_NN of_IN high_JJ frequency_NN
          oscillations_NNS )_) ;_: amplitude_NN of_IN high_JJ frequency_NN oscillations_NNS ._.
          The_DT EMG_NNP activity_NN was_VBD examined_VBN by_IN dividing_VBG the_DT bladder_NN
          contraction_NN into_IN three_CD phases_NNS in_IN a_DT modification_NN of_IN the_DT
          technique_NN of_IN Chien_NNP et_CC al_NN ._. [_NN 19_CD ]_NN a_DT contraction_NN phase_NN
          (_( phase_NN 1_LS )_) ;_: an_DT expulsion_NN phase_NN (_( phase_NN 2_LS )_) and_CC a_DT closing_NN
          phase_NN (_( phase_NN 3_LS )_) ._.
          The_DT raw_JJ EMG_NNP was_VBD rectified_VBN ,_, integrated_VBN (_( 0_CD ._. 5_LS second_JJ bin_NN )_)
          and_CC the_DT area_NN under_IN curve_NN of_IN the_DT EMG_NNP corresponding_JJ to_TO each_DT
          phase_NN of_IN the_DT bladder_NN contraction_NN was_VBD measured_VBN (_( Sigma_NNP
          Scan_NNP /_NN Image_NN ;_: Jandel_NNP Scientiflcs_NNP ,_, San_NNP Rafael_NNP ,_, Ca_MD )_) ._. Drug_NN
          effects_NNS for_IN the_DT EMG_NNP were_VBD calculated_VBN as_IN percent_NN of_IN
          control_NN ._.
          Values_NNP are_VBP presented_VBN as_IN Mean_VB +_NN S_NNP ._. E_NNP ._. M_NNP ._. Repeated_NNP
          measures_NNS ANOVA_NNP (_( GB_NNP Stat_NNP ;_: Dynamic_NNP Microsystems_NNPS ;_: MD_NNP )_) were_VBD
          performed_VBN on_IN all_DT parameters_NNS and_CC when_WRB statistical_JJ
          significance_NN (_( p_NN <_NN 0_CD ._. 05_CD )_) was_VBD obtained_VBN ,_, comparisons_NNS
          between_IN control_NN and_CC different_JJ drug_NN dosages_NNS and_CC between_IN
          different_JJ routes_NNS (_( i_NNP ._. t_NN ._. vs_NNS ._. i_NNP ._. c_SYM ._. v_NN ._. )_) were_VBD made_VBN using_VBG
          Fisher_NNP 's_POS protected_VBN t-test_JJ [_NN 35_CD ]_NN ._.
        
      
      
        List_NN of_IN Abbreviations_NNP
        CMG_NNP =_SYM cystometrogram_NN
        EMG_NNP =_SYM electromyogram_NN
        EUS_NNP =_SYM external_JJ urethral_NN sphincter_NN
        HFO_NNP =_SYM high_JJ frequency_NN oscillations_NNS
        i_NNP ._. c_SYM ._. v_NN ._. =_SYM intracerebroventricular_NN
        i_NNP ._. t_NN ._. =_SYM intrathecal_NN
        i_NNP ._. v_NN ._. =_SYM intravenous_JJ
      
    
  
